Joseph P Roche1, Andrew J Goates, David M Hasan, Matthew A Howard, Arnold H Menezes, Marlan R Hansen, Bruce J Gantz. 1. *Division of Otolaryngology, Department of Surgery, School of Medicine and Public Health, The University of Wisconsin, Madison, Wisconsin †Department of Otolaryngology-Head and Neck Surgery ‡The Department of Neurosurgery, The University of Iowa Carver College of Medicine, The University of Iowa, Iowa City, Iowa.
Abstract
OBJECTIVE: Define the indications and outcomes for subjects undergoing treatment utilizing the extended middle cranial fossa approach (EMCF). STUDY DESIGN: Retrospective records review. SETTING: University-based tertiary referral center. PATIENTS: Subjects undergoing treatment of posterior cranial fossa (PCF) lesions. INTERVENTION(S): EMCF exposure and treatment of the indicating PCF lesion. MAIN OUTCOME MEASURE(S): Demographic, audiometric, and cranial nerve functioning variables were assessed. RESULTS: Thirty-five subjects who underwent an EMCF exposure were identified over a 12-year period. The most common indication was meningioma (18; 51%) followed by schwannomas (six, 17%), and vascular lesions (five, 14%). Preoperative cranial nerve complaints were common (32, 94%) as were objective cranial nerve abnormalities on physical examination (21; 60%). Preoperative audiometric data from subjects with hearing demonstrated good functioning including pure-tone average (PTA) (21.7 ± 15.6 dB HL) and word understanding scores (95.1 ± 7.4%). Most (34, 97%) subjects had intact facial nerve function. The average length of stay was 11.6 days (median = 9). Cranial neuropathies were common postoperatively with 27 (79%) subjects demonstrating some objective cranial nerve dysfunction, the most common of which was trigeminal nerve hypesthesia (21, 61.7%). Subjects with identifiable pre- and postoperative audiometric data and preoperative hearing demonstrated small declines in the four-tone average (16.2 dB) and word recognition scores (22.4%). Two subjects (6%) had new profound hearing loss postoperatively. CONCLUSIONS: The EMCF approach can provide safe and effective exposure of the anterior PCF.
OBJECTIVE: Define the indications and outcomes for subjects undergoing treatment utilizing the extended middle cranial fossa approach (EMCF). STUDY DESIGN: Retrospective records review. SETTING: University-based tertiary referral center. PATIENTS: Subjects undergoing treatment of posterior cranial fossa (PCF) lesions. INTERVENTION(S): EMCF exposure and treatment of the indicating PCF lesion. MAIN OUTCOME MEASURE(S): Demographic, audiometric, and cranial nerve functioning variables were assessed. RESULTS: Thirty-five subjects who underwent an EMCF exposure were identified over a 12-year period. The most common indication was meningioma (18; 51%) followed by schwannomas (six, 17%), and vascular lesions (five, 14%). Preoperative cranial nerve complaints were common (32, 94%) as were objective cranial nerve abnormalities on physical examination (21; 60%). Preoperative audiometric data from subjects with hearing demonstrated good functioning including pure-tone average (PTA) (21.7 ± 15.6 dB HL) and word understanding scores (95.1 ± 7.4%). Most (34, 97%) subjects had intact facial nerve function. The average length of stay was 11.6 days (median = 9). Cranial neuropathies were common postoperatively with 27 (79%) subjects demonstrating some objective cranial nerve dysfunction, the most common of which was trigeminal nerve hypesthesia (21, 61.7%). Subjects with identifiable pre- and postoperative audiometric data and preoperative hearing demonstrated small declines in the four-tone average (16.2 dB) and word recognition scores (22.4%). Two subjects (6%) had new profound hearing loss postoperatively. CONCLUSIONS: The EMCF approach can provide safe and effective exposure of the anterior PCF.
Authors: Ted Shen; Rick A Friedman; Derald E Brackmann; William H Slattery; William E Hitselberger; Marc S Schwartz; Laurel Fisher Journal: Otol Neurotol Date: 2004-05 Impact factor: 2.311
Authors: Daniel Q Sun; Arnold H Menezes; Matthew A Howard; Bruce J Gantz; David M Hasan; Marlan R Hansen Journal: Otol Neurotol Date: 2018-01 Impact factor: 2.311
Authors: Elizabeth L Perkins; Nauman F Manzoor; David S Haynes; Matthew O'Malley; René Gifford; Alejandro Rivas Journal: Otol Neurotol Date: 2021-07-01 Impact factor: 2.311
Authors: Ali S Farooqi; Starr Jiang; Austin J Borja; Donald K E D Detchou; Ryan Dimentberg; Kaitlyn Shultz; Scott D McClintock; Neil R Malhotra Journal: Cureus Date: 2021-11-29
Authors: Nauman F Manzoor; Peter Morone; Patrick D Kelly; Silky Chotai; Robert J Yawn; Lola B Chambless; Reid C Thompson; Alejandro Rivas Journal: J Neurol Surg B Skull Base Date: 2020-03-28